Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-β-Lactamase, in a Tertiary Care Center in Cali, Colombia
暂无分享,去创建一个
M. Kaufmann | N. Woodford | D. Livermore | J. Turton | M. E. Kaufmann | D. M. Livermore | M. P. Crespo | N. Woodford | A. Sinclair | J Turton | J. Glover | J. D. Velez | C. R. Castañeda | M. Recalde | J. Vélez | M. Crespo | A. Sinclair | J. Glover | C. R. Castaneda | M. Recalde
[1] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[2] R. W. Davis,et al. Separation of large DNA molecules by contour-clamped homogeneous electric fields. , 1986, Science.
[3] T. Pitt. Epidemiological typing of Pseudomonas aeruginosa. , 1988, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
[4] T. Pitt,et al. Resistance mechanisms of multiresistant serotype 012 Pseudomonas aeruginosa isolated in Europe. , 1990, Journal of Antimicrobial Chemotherapy.
[5] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .
[6] S. Ichiyama,et al. Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems , 1996, Antimicrobial agents and chemotherapy.
[7] M. Rué,et al. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] T. Pitt,et al. Epidemiologically related and unrelated strains of Pseudomonas aeruginosa serotype O12 cannot be distinguished by phenotypic and genotypic typing. , 1997, The Journal of hospital infection.
[9] Pan‐Chyr Yang,et al. Persistence of a Multidrug-ResistantPseudomonas aeruginosa Clone in an Intensive Care Burn Unit , 1998, Journal of Clinical Microbiology.
[10] N. Woodford,et al. Carbapenemase-producing Pseudomonas aeruginosa in UK , 1998, The Lancet.
[11] Yasuaki Yamada,et al. Rapid Detection and Evaluation of Clinical Characteristics of Emerging Multiple-Drug-Resistant Gram-Negative Rods Carrying the Metallo-β-Lactamase GeneblaIMP , 1998, Antimicrobial Agents and Chemotherapy.
[12] G. Cornaglia,et al. Appearance of IMP-1 metallo-β-lactamase in Europe , 1999, The Lancet.
[13] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[14] N. Woodford,et al. Carbapenemases: a problem in waiting? , 2000, Current opinion in microbiology.
[15] N. Woodford,et al. Outbreak of Infections Caused by Pseudomonas aeruginosa Producing VIM-1 Carbapenemase in Greece , 2000, Journal of Clinical Microbiology.
[16] S. Pournaras,et al. Carbapenem-hydrolysing VIM-2 metallo- beta-lactamase in Pseudomonas aeruginosa from Greece. , 2000, The Journal of antimicrobial chemotherapy.
[17] G. Cornaglia,et al. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Ronald N. Jones,et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] J. Wu,et al. Metallo-β-Lactamases in ClinicalPseudomonas Isolates in Taiwan and Identification of VIM-3, a Novel Variant of the VIM-2 Enzyme , 2001, Antimicrobial Agents and Chemotherapy.
[20] J. Andrews,et al. Determination of minimum inhibitory concentrations. , 2001, The Journal of antimicrobial chemotherapy.
[21] N. Gotoh,et al. Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical Isolates , 2001, Antimicrobial Agents and Chemotherapy.
[22] J. Verhoef,et al. Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa. , 2002, The Journal of antimicrobial chemotherapy.
[23] D. Livermore,et al. bla VIM-2 Cassette-Containing Novel Integrons in Metallo-β-Lactamase-Producing Pseudomonas aeruginosa and Pseudomonas putida Isolates Disseminated in a Korean Hospital , 2002, Antimicrobial Agents and Chemotherapy.
[24] Richard A. Moore,et al. Nosocomial Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa with a New blaIMP Allele, blaIMP-7 , 2002, Antimicrobial Agents and Chemotherapy.
[25] H. Shin,et al. Imipenem-EDTA Disk Method for Differentiation of Metallo-β-Lactamase-Producing Clinical Isolates of Pseudomonas spp. and Acinetobacter spp , 2002, Journal of Clinical Microbiology.
[26] Ronald N. Jones,et al. Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. , 2002, The Journal of antimicrobial chemotherapy.
[27] P. Hsueh,et al. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. , 2002, The Journal of antimicrobial chemotherapy.
[28] P. Nordmann,et al. Emerging carbapenemases in Gram-negative aerobes. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[29] H. Giamarellou. Prescribing guidelines for severe Pseudomonas infections. , 2002, The Journal of antimicrobial chemotherapy.
[30] N. Woodford,et al. IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. , 2002, The Journal of antimicrobial chemotherapy.
[31] A. Barth,et al. Antibiotic resistance and molecular typing of Pseudomonas aeruginosa: focus on imipenem. , 2002, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
[32] R. Scott,et al. The global impact of drug resistance. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] E. Petinaki,et al. Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4. , 2003, The Journal of antimicrobial chemotherapy.
[34] Yasuaki Yamada,et al. Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] A. Gales,et al. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. , 2003, The Journal of antimicrobial chemotherapy.
[36] Ronald N. Jones,et al. Genetic characterization of a novel metallo-beta-lactamase gene, blaIMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. , 2003, The Journal of antimicrobial chemotherapy.
[37] Ronald N. Jones,et al. Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. , 2003, Diagnostic microbiology and infectious disease.